Ellomay Capital Ltd. current report, Q2 FY2001

Business Context and Reporting Period

Company: NUR Macroprinters Ltd. (Note: Metadata listed "Ellomay Capital Ltd." but the filing text identifies the registrant as NUR Macroprinters Ltd.)
Reporting Period: First Quarter ended March 31, 2001.
Business: Global manufacturer of wide and superwide format digital printing systems and consumables.

Key Financial Metrics

Metric Q1 2001 (As Reported) Q1 2001 (Pro Forma) Q1 2000 (As Reported)
Revenue $31.4 million $31.4 million $21.5 million
Gross Profit $9.0 million $13.0 million $9.8 million
Gross Margin 28.7% 41.4% 45.6%
Operating Income (Loss) ($5.5 million) $1.0 million $2.9 million
Net Income (Loss) ($6.6 million) ($0.04 million) $2.5 million
Diluted EPS ($0.45) $0.00 $0.18
Cash and Equivalents $14.0 million N/A N/A
Total Debt (Short + Long Term) $34.7 million N/A N/A

Note: Pro forma figures exclude $2.5 million in restructuring costs and $4.0 million in one-time inventory write-offs.

Material Changes vs. Prior Period

  • Revenue Growth: Increased 47% year-over-year to $31.4 million, though management noted this was lower than expected due to a slowdown in the North American market.
  • Profitability Decline: As-reported net loss of $6.6 million compared to net income of $2.5 million in Q1 2000. This shift is primarily driven by $6.5 million in non-recurring charges (restructuring and inventory write-offs).
  • Operating Expenses: Pro forma operating expenses increased 64% to $12.0 million, largely due to amortization of intangibles ($0.7 million) and interest expenses ($0.6 million) related to the Salsa Digital acquisition.
  • Liquidity: Cash and cash equivalents decreased 27% to $14.0 million from $19.2 million at year-end 2000.

Guidance, Outlook, and Strategic Initiatives

  • Strategic Cost Cutting: The company announced a strategic initiative to cut costs and eliminate redundancies. Approximately 70 staff positions (14% of the workforce) were eliminated.
  • Operational Consolidation: U.S. operations are being consolidated into a single facility in San Antonio, Texas. Ink R&D operations are being consolidated into a single facility in Charleroi, Belgium.
  • Acquisition: NUR acquired the remaining 50% of its Stillachem S.A. ink manufacturing operation. Terms were not disclosed.
  • Future Savings: Management expects the cost-saving measures to result in approximately $4 million in additional savings over the next twelve months.
  • Outlook: Management remains confident in long-term opportunities driven by digital technology replacing traditional printing, citing strong demand for the NUR Fresco 3,200 and NUR Salsa Ultima models.
  • Risks: Forward-looking statements highlight risks including general economic slowdowns, decline in product demand, inability to develop new technologies, and competitive price pressure.

Investor Verification Checklist

  • Verify the impact of the $6.5 million in one-time charges (restructuring and inventory write-offs) on future quarters.
  • Confirm the timeline and actual savings realized from the consolidation of U.S. and European operations.
  • Monitor the North American market recovery, which was cited as the primary cause for revenue shortfall.
  • Review the terms and financial impact of the full acquisition of Stillachem S.A.
  • Assess the company's ability to maintain liquidity given the 27% drop in cash reserves and current debt levels.